Mitsubishi UFJ Asset Management Portfolio holdings
AUM
$125B
1-Year Return
23.89%
This Quarter Return
-2.8%
1 Year Return
+23.89%
3 Year Return
+93.04%
5 Year Return
+163.06%
10 Year Return
+400.91%
AUM
$49.4B
AUM Growth
+$1.51B
(+3.2%)
Cap. Flow
+$3.25B
Cap. Flow
% of AUM
6.57%
Top 10 Holdings %
Top 10 Hldgs %
27.38%
Holding
1,558
New
448
Increased
789
Reduced
207
Closed
14
Top Buys
| 1 |
Apple
AAPL
|
+$174M |
| 2 |
Thermo Fisher Scientific
TMO
|
+$145M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$119M |
| 4 |
Microsoft
MSFT
|
+$118M |
| 5 |
Coca-Cola
KO
|
+$94M |
Top Sells
| 1 |
Adobe
ADBE
|
+$62.6M |
| 2 |
Danaher
DHR
|
+$31.8M |
| 3 |
Amphenol
APH
|
+$27.5M |
| 4 |
SPDR Bloomberg High Yield Bond ETF
JNK
|
+$26.6M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$24.4M |
Sector Composition
| 1 | Technology | 28.77% |
| 2 | Healthcare | 16.06% |
| 3 | Financials | 13.69% |
| 4 | Consumer Discretionary | 8.74% |
| 5 | Consumer Staples | 7.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1001
Recursion Pharmaceuticals
RXRX
$2.05B
| $252K | ﹤0.01% |
33,002
+1,938
| +6% | +$14.8K |
|
1002
Roivant Sciences
ROIV
$8.82B
| $251K | ﹤0.01% |
21,450
| – | – |
|
1003
Regenxbio
RGNX
$479M
| $239K | ﹤0.01% |
14,539
+870
| +6% | +$14.3K |
|
|
BLUE
1004
DELISTED
bluebird bio
BLUE
| $237K | ﹤0.01% |
3,900
+238
| +6% | +$14.5K |
|
1005
Ionis Pharmaceuticals
IONS
$10.3B
| $236K | ﹤0.01% |
5,195
+95
| +2% | +$4.31K |
|
|
DHC
1006
Diversified Healthcare Trust
DHC
$1.04B
| $236K | ﹤0.01% |
121,394
-28,212
| -19% | -$54.7K |
|
1007
Editas Medicine
EDIT
$251M
| $229K | ﹤0.01% |
29,387
| – | – |
|
1008
Sarepta Therapeutics
SRPT
$1.85B
| $228K | ﹤0.01% |
1,881
+43
| +2% | +$5.21K |
|
1009
Marqeta
MQ
$2.73B
| $225K | ﹤0.01% |
37,577
-2,983
| -7% | -$17.8K |
|
1010
Forum Energy Technologies
FET
$312M
| $224K | ﹤0.01% |
9,341
-363
| -4% | -$8.72K |
|
|
SOL
1011
Emeren Group
SOL
$97M
| $223K | ﹤0.01% |
72,247
+408
| +0.6% | +$1.26K |
|
|
ALX
1012
Alexander's
ALX
$1.2B
| $220K | ﹤0.01% |
1,205
+18
| +2% | +$3.28K |
|
|
VERV
1013
DELISTED
Verve Therapeutics
VERV
| $219K | ﹤0.01% |
16,479
+871
| +6% | +$11.5K |
|
1014
Intellia Therapeutics
NTLA
$1.28B
| $210K | ﹤0.01% |
6,651
+451
| +7% | +$14.3K |
|
1015
Arrowhead Research
ARWR
$3.76B
| $209K | ﹤0.01% |
7,762
+210
| +3% | +$5.64K |
|
1016
Xencor
XNCR
$600M
| $208K | ﹤0.01% |
10,347
+369
| +4% | +$7.44K |
|
1017
Q2 Holdings
QTWO
$5.25B
| $208K | ﹤0.01% |
6,458
-368
| -5% | -$11.9K |
|
1018
Sanofi
SNY
$116B
| $208K | ﹤0.01% |
3,880
+418
| +12% | +$22.4K |
|
1019
CureVac
CVAC
$1.21B
| $208K | ﹤0.01% |
30,435
+1,635
| +6% | +$11.2K |
|
1020
Maravai LifeSciences
MRVI
$353M
| $206K | ﹤0.01% |
20,619
+1,170
| +6% | +$11.7K |
|
1021
CRISPR Therapeutics
CRSP
$4.88B
| $204K | ﹤0.01% |
4,484
+76
| +2% | +$3.45K |
|
1022
Novartis
NVS
$249B
| $203K | ﹤0.01% |
1,995
+105
| +6% | +$10.7K |
|
1023
Ultragenyx Pharmaceutical
RARE
$3.04B
| $198K | ﹤0.01% |
5,568
+79
| +1% | +$2.82K |
|
|
ONL
1024
Orion Office REIT
ONL
$171M
| $197K | ﹤0.01% |
37,889
| – | – |
|
1025
4D Molecular Therapeutics
FDMT
$326M
| $194K | ﹤0.01% |
15,278
+820
| +6% | +$10.4K |
|